Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.40 |
| ▸ | CACNG2 | Q9Y698 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457302 | 0.91 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL5457248 | 0.89 | MAPK14 (0.64) | MAPK14ALOX5 | |
| SCHEMBL5451210 | 0.88 | MAPK14 (0.48) | MAPK14GRIA1CACNG2CYP2C8CYP2C9 | |
| SCHEMBL5211998 | 0.85 | ADORA3 (0.37) | MAPK14FYNTP53MAPTRXFP1 | |
| SCHEMBL5456838 | 0.83 | CSNK1D (0.51) | MAPK14 | |
| SCHEMBL5454714 | 0.82 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL5462491 | 0.82 | CSNK1D (0.51) | MAPK14 | |
| SCHEMBL5455358 | 0.81 | MAPK14 (0.42) | MAPK14GRIA1ALOX5 | |
| SCHEMBL6184465 | 0.80 | GSK3B (0.55) | MAPK14 | |
| SCHEMBL5452090 | 0.80 | MAPK14 (0.55) | MAPK14GRIA1CACNG2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | MAPK14 2533/4885GRIA1 3506/4885CACNG2 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.